- Home
- SSP vs ABOS Comparison
SSP vs ABOS Comparison
Compare SSP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- ABOS
- Stock Information
- Founded
- SSP 1878
- ABOS 1996
- Country
- SSP United States
- ABOS United States
- Employees
- SSP N/A
- ABOS N/A
- Industry
- SSP Broadcasting
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- ABOS Health Care
- Exchange
- SSP Nasdaq
- ABOS Nasdaq
- Market Cap
- SSP 173.3M
- ABOS 166.4M
- IPO Year
- SSP 1988
- ABOS 2021
- Fundamental
- Price
- SSP $1.71
- ABOS $2.41
- Analyst Decision
- SSP Buy
- ABOS Strong Buy
- Analyst Count
- SSP 2
- ABOS 4
- Target Price
- SSP $7.75
- ABOS $9.00
- AVG Volume (30 Days)
- SSP 652.1K
- ABOS 185.7K
- Earning Date
- SSP 11-01-2024
- ABOS 08-13-2024
- Dividend Yield
- SSP N/A
- ABOS N/A
- EPS Growth
- SSP N/A
- ABOS N/A
- EPS
- SSP N/A
- ABOS N/A
- Revenue
- SSP $2,317,391,000.00
- ABOS N/A
- Revenue This Year
- SSP $8.99
- ABOS N/A
- Revenue Next Year
- SSP N/A
- ABOS N/A
- P/E Ratio
- SSP N/A
- ABOS N/A
- Revenue Growth
- SSP N/A
- ABOS N/A
- 52 Week Low
- SSP $1.77
- ABOS $1.81
- 52 Week High
- SSP $9.35
- ABOS $5.76
- Technical
- Relative Strength Index (RSI)
- SSP 30.43
- ABOS 33.19
- Support Level
- SSP $1.99
- ABOS $2.15
- Resistance Level
- SSP $2.19
- ABOS $2.92
- Average True Range (ATR)
- SSP 0.13
- ABOS 0.17
- MACD
- SSP -0.00
- ABOS -0.06
- Stochastic Oscillator
- SSP 0.00
- ABOS 8.32
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.